|
|
Library
|
|
|
|
|
|
| |
|
Timeframe
|
|
|
|
|
Category
|
|
|
| |
|
Sub-Category
|
|
|
|
| ** To make multiple selections, select the first criterion and then press and hold
the Ctrl Key **
|
|
| |
|
1- 1 of 1
Search Results for:
|
Ordering of Search Results
When searching across multiple libraries:
FAQs will appear in alphabetical order by category and sub-category
Listing Council Decisions will appear in reverse chronological order by year.
Staff Interpretations will appear in reverse chronological order by year
When searching using keywords:
Results are returned in order of term frequency (i.e., the number of times the keywords appear in the material).
|
|
Libraries:
Staff Interpretation Letters
|
|
Filters:
All Years; Shareholder Approval; All
|
|
|
|
|
Identification Number
868
|
|
|
This is in response to your letters regarding the applicability of The NASDAQ Stock Market’s shareholder approval requirements to an issuance of securities in a private placement (the “Transaction”). Specifically, you asked about the potential applicability
of Marketplace Rules 4350(i)(1)(B) and 4350(i)(1)(D) (the “Rules”) to the Transaction.
According to the information you provided, in the Transaction, the company expects to issue to institutional investors shares of common stock (the “Shares”) and warrants to purchase additional shares of common stock (the “Investor Warrants”). The Shares
will equal approximately 19.6% of the pre-transaction outstanding shares of common stock, and the warrants, approximately 4.9%. In addition, the company will issue to the placement agent warrants to purchase shares of common stock (the “Placement Agent Warrants”,
and collectively with the Investor Warrants, the “Warrants”). The exercise price of the Warrants will not be less than the closing bid of the common stock immediately preceding the execution of the definitive agreement (the “Market Value”). The Warrants may
not be exercised for 180 days following closing and will not be subject to any adjustment provision that could reduce the exercise price to less than Market Value. You stated that no officer, director, employee, or consultant of the company will participate
in the Transaction. In addition, no investor individually, or as part of a group, can beneficially own, or have the right to acquire, more than 19.99% of the company’s outstanding common shares or the voting power of the company on a post-transaction basis.
Following our review of the information you submitted, we have concluded that the Transaction as described in your correspondence does not require shareholder approval under the Rules. Specifically, the Transaction does not require shareholder approval
under Listing Rule 4350(i)(1)(D) because the issuance of the Shares, although at a price less than market value, will equal less than 20% of the common shares and voting power outstanding on a pre-transaction basis. The exercise price of the Warrants will
be not be less than the greater of book and market value, and the Warrants may not be exercised until 180 days from the date of closing. Further, given the ownership restrictions described above, the Transaction will not result in a change of control and
will not require shareholder approval under Listing Rule 4350(i)(1)(B).
|
Publication Date*:
7/31/2012
|
|
|
Identification Number:
868
|
|
|
|
|